| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1009277848 |
| P356 | DOI | 10.1007/BF00046346 |
| P8608 | Fatcat ID | release_xh67xiwul5cjrmorhyuewjl4i4 |
| P698 | PubMed publication ID | 9034595 |
| P2093 | author name string | L S Young | |
| P F Searle | |||
| P2860 | cites work | Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer | Q71829530 |
| In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes | Q71887324 | ||
| Active intralymphatic immunotherapy of uterine cervical carcinoma with viral oncolysate: a pilot study | Q74572658 | ||
| Effective immune rejection of advanced metastasized cancer | Q84070634 | ||
| CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1 | Q24296934 | ||
| Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor | Q24312048 | ||
| Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection | Q24561706 | ||
| Antigen processing in vivo and the elicitation of primary CTL responses | Q24675502 | ||
| CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation | Q24678846 | ||
| CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones | Q28209894 | ||
| Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 | ||
| The role of the CD28 receptor during T cell responses to antigen | Q28263234 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 | Q28284177 | ||
| CD43 is a murine T cell costimulatory receptor that functions independently of CD28 | Q28586182 | ||
| Differential T cell costimulatory requirements in CD28-deficient mice | Q28590647 | ||
| The ubiquitin-proteasome proteolytic pathway | Q29618638 | ||
| Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity | Q29619700 | ||
| HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2 | Q30452144 | ||
| Structure of peptides associated with class I and class II MHC molecules | Q30463866 | ||
| Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens | Q33714644 | ||
| Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity | Q33956237 | ||
| Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 | ||
| Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans | Q34345458 | ||
| Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide | Q34765735 | ||
| Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells | Q35227334 | ||
| Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes | Q35782803 | ||
| Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses | Q35793550 | ||
| Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen | Q35945206 | ||
| Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. | Q36088999 | ||
| Immunotherapy of malignancy by in vivo gene transfer into tumors | Q36309790 | ||
| Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain | Q36361920 | ||
| Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity | Q36362788 | ||
| T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. | Q36363017 | ||
| Proliferating dendritic cell progenitors in human blood | Q36363279 | ||
| Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit | Q71483389 | ||
| Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity | Q71563753 | ||
| Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins | Q71616385 | ||
| T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector | Q71625124 | ||
| Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood | Q71675462 | ||
| Identification of a unique costimulatory activity for murine T helper 1 T cell clones | Q71689100 | ||
| Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro | Q71693348 | ||
| The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer | Q71803276 | ||
| A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours | Q71803282 | ||
| Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine | Q71804669 | ||
| Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro | Q71805057 | ||
| Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients | Q71820107 | ||
| Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin | Q71828992 | ||
| Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function | Q36363597 | ||
| A reassessment of the role of B7-1 expression in tumor rejection. | Q36365375 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors | Q36366207 | ||
| Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules | Q36370334 | ||
| Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer | Q36745744 | ||
| Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen | Q37360322 | ||
| Immunotherapy for malignant melanoma: a review and update | Q37404488 | ||
| Selective protein degradation: a journey's end within the proteasome | Q40410581 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors | Q40673030 | ||
| IL-12: initiation cytokine for cell-mediated immunity | Q40709472 | ||
| Potential immunogenicity of oncogene and tumor suppressor gene products | Q40780216 | ||
| Natural history of HLA expression during tumour development. | Q40797268 | ||
| The biochemistry and cell biology of antigen processing and presentation | Q40898211 | ||
| HLA class I antigens in human tumors. | Q40951674 | ||
| Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation | Q40968403 | ||
| Blood stem cell transplantation and gene therapy of cancer | Q41070902 | ||
| Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. | Q41239385 | ||
| In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation | Q41282357 | ||
| The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro | Q41283840 | ||
| Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors | Q41304280 | ||
| Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. | Q41343013 | ||
| Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 | Q41589138 | ||
| Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells | Q41694270 | ||
| B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy | Q42675165 | ||
| Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. | Q42810754 | ||
| B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. | Q42828319 | ||
| Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein | Q42941680 | ||
| The cleavage preference of the proteasome governs the yield of antigenic peptides. | Q42943174 | ||
| Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells | Q44615042 | ||
| Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation | Q44618759 | ||
| Direct gene transfer into mouse muscle in vivo | Q44656494 | ||
| Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma | Q45752822 | ||
| Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation | Q45780110 | ||
| Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules | Q45866282 | ||
| A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity | Q45868797 | ||
| Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. | Q46032484 | ||
| Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients | Q51165232 | ||
| Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope | Q52049430 | ||
| Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. | Q54598220 | ||
| B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro | Q56909166 | ||
| Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules | Q56909474 | ||
| B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum | Q56909614 | ||
| GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells | Q59067424 | ||
| Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells | Q67689822 | ||
| Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma | Q67753693 | ||
| Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity | Q70852128 | ||
| B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct | Q70890739 | ||
| Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor | Q70932818 | ||
| Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells | Q70993699 | ||
| Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells | Q71436495 | ||
| P433 | issue | 3 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 329-349 | |
| P577 | publication date | 1996-09-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cancer and Metastasis Reviews | Q2647982 |
| P1476 | title | Immunotherapy II: Antigens, receptors and costimulation | |
| P478 | volume | 15 |
| Q46971015 | Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. |
| Q34187915 | Gene therapy: development of immunostimulatory treatments for cancer |
| Q35753328 | Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. |
| Q38292169 | The potential role of immunotherapy to treat colorectal cancer |
Search more.